Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

(2010) Dawn L. Hershman et al.   BREAST CANCER RESEARCH AND TREATMENT

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

(2010) HT Mouridsen et al.   CANCER RESEARCH

Cardiac Mass in a Rapidly Deteriorating Patient

(2010) Alona Zer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

(2010) Michael P. Lux et al.   ONKOLOGIE

Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study

(2010) Michael P. Lux et al.   ONKOLOGIE

Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model

(2009) Michael Patrick Lux et al.   BREAST CANCER RESEARCH AND TREATMENT

Is the biology of breast cancer changing? A study of hormone receptor status 1984–1986 and 1996–1997

(2009) S B F Brown et al.   BRITISH JOURNAL OF CANCER

Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes

(2009) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

Ist ein Brustzentrum finanzierbar? – Berechnung einzelner Leistungen am Beispiel des Universitäts-Brustzentrums Franken (UBF)

(2008) S. Wagner et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Primary endpoints for randomised trials of cancer therapy

(2008) Jack Cuzick   LANCET

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY